Latest News for: inhibitor

Edit

InnoCare Announces First Patient Dosed in the Phase II/III Clinical Trial of Novel TYK2 Inhibitor ...

Nasdaq Globe Newswire 13 Feb 2026
The current indications of soficitinib under development are strategically positioned within the vast dermatology market ... .
Edit

Mold Inhibitors Market Size to be Valued at USD 2.20 Billion by 2033 Owing to ...

Nasdaq Globe Newswire 13 Feb 2026
Mold Inhibitors Market to reach USD 2.20B by 2033, driven by clean-label demand, food safety needs, and rising bio-based adoption globally ... .
Edit

BCL-2 Inhibitors Market Poised for Robust Growth During the Forecast Period (2025-2034) as Oncology Pipelines Expand | DelveInsight

PR Newswire 12 Feb 2026
In 2024, the United States holds the largest share of the BCL-2 inhibitors market among the 7MM ... Learn more about who are the leading companies in BCL-2 inhibitors @ BCL-2 Inhibitors Analysis. BCL-2 Inhibitors Competitive Landscape.
Edit

Unexpected Cancer Drug Combo Shows Stronger Results Against Ovarian Tumors

Mega Doctor News 12 Feb 2026
A new study published by Mayo Clinic researchers suggests that ovarian cancer cells quickly activate a survival response after PARP inhibitor treatment, and blocking this early response may make this class of drugs work better.
Edit

Adlai Nortye Announces First Patient Enrolled in Global Phase 1 Trial of Pan-RAS (ON) Inhibitor

Hastings Tribune 12 Feb 2026
SINGAPORE and NORTH BRUNSWICK, N.J ... (NASDAQ.
Edit

Power supply issues flagged as major growth inhibitor of European datacentre market

Computer Weekly 12 Feb 2026
Power availability is the European datacentre market’s “single most important” growth inhibitor, forcing operators to look further afield for sites with abundant renewable energy to meet the growing ...
Edit

J INTS BIO Reports Fourth-Generation EGFR Inhibitor JIN-A02 in Clinical Cancer Research

PR Newswire 12 Feb 2026
announced that research findings on its investigational fourth-generation EGFR tyrosine kinase inhibitor (TKI), ... J INTS BIO Reports Fourth-Generation EGFR Inhibitor JIN-A02 in Clinical Cancer Research.
Edit

Adlai Nortye Announces First Patient Enrolled in Global Phase 1 Trial of Pan-RAS (ON) Inhibitor AN9025 for Solid Tumors Harboring RAS Mutations (Form 6-K) (Adlai Nortye Ltd)

Public Technologies 12 Feb 2026
Adlai Nortye Announces First Patient Enrolled in Global Phase 1 Trial of Pan-RAS (ON) Inhibitor AN9025 for Solid Tumors Harboring RAS Mutations ... 1 clinical trial of AN9025, a pan-RAS (ON) inhibitor.
Edit

Iterion Therapeutics Announces First Patient Dosed in Clinical Study of Tegavivint, a First-in-Class Wnt/β-Catenin Inhibitor, ...

The Bismarck Tribune 11 Feb 2026
Tegavivint Is the First Wnt/β-Catenin Inhibitor to Demonstrate Tolerability and Monotherapy Clinical Activity in Complex Solid Tumors ... .
Edit

Enanta Pharmaceuticals to Present Preclinical Data for EDP-978, its KIT Inhibitor in Development for the ...

The Galveston Daily News 10 Feb 2026
WATERTOWN, Mass.--(BUSINESS WIRE)--Feb 10, 2026-- ....
Edit

Enanta Pharmaceuticals to Present Preclinical Data for EDP-978, its KIT Inhibitor in Development for the Treatment of Type 2 Immune Diseases, at the 2026 AAAAI Annual Meeting

Pharmiweb 10 Feb 2026
Discovery of a Potent and Selective KIT inhibitor for Treatment of Mast Cell-Mediated Diseases ... EDP-978, a Potent KIT Inhibitor, Demonstrated Dose-Dependent Target-Engagement and a Favorable ...
Edit

Iterion Therapeutics Announces First Patient Dosed in Clinical Study of Tegavivint, a First-in-Class Wnt/β-Catenin Inhibitor, in Relapsed/Refractory Osteosarcoma

PR Newswire 10 Feb 2026
Tegavivint Is the First Wnt/β-Catenin Inhibitor to Demonstrate Tolerability and Monotherapy Clinical Activity in Complex Solid Tumors ... Tegavivint is a small-molecule inhibitor of TBL1, a ...
Edit

PI3K Inhibitors Market & Clinical Trials Outlook: Evaluating 25+ Drug Candidates Across 20+ Active Companies ...

GetNews 06 Feb 2026
"PI3K Inhibitors Pipeline" ... DelveInsight’s “PI3K Inhibitors Pipeline Insight” delivers an extensive global assessment of PI3K inhibitors currently under clinical development across various stages ... PI3K Inhibitors.
Edit

Barbacid Cures Pancreatic Cancer in Mice – Now Needs Funding for Humans

Greek City Times 06 Feb 2026
....
Edit

Insilico Medicine Nominates ISM5059, the Peripheral-restricted NLRP3 Inhibitor as Preclinical Candidate, for the Treatment of Multiple Inflammatory and Metabolism Indications

PR Newswire 05 Feb 2026
Insilico Medicine (3696.HK), a clinical-stage, generative AI-driven drug discovery company, today announced the nomination of ISM5059, an AI-empowered, peripherally restricted small molecule inhibitor ...

Article Search

tools
×
×
×
×